RE:call me crazyI hear you. KNR has done well for pre-BioCloud shareholders, and oversold the story to the BioCloud shareholders. Many of us with high costs may partly invest not because of perceived value but giving our investment a fighting chance. I may be wrong, but I somehow can't see the pre-BioCloud shareholders "taking advantage of this opportunity" and averaging up significantly. KNR has to step up to the plate and fix its miscommunication...too late for a week ago, but tomorrow is the next best time. Write the company and insist on it for your own good.